Publikasi Scopus 2010 s/d 2022

Lesmana C.R.A., Paramitha M.S., Hasan I.
8977683000;57212562901;12776850800;
1.34 - Gut Microbiota Dysbiosis in Non-alcoholic Fatty Liver Disease
2022
Comprehensive Gut Microbiota
1
475
488
Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Digestive Disease & GI Oncology Center, Medistra Hospital, Jakarta, Indonesia
Lesmana, C.R.A., Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia, Digestive Disease & GI Oncology Center, Medistra Hospital, Jakarta, Indonesia; Paramitha, M.S., Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia; Hasan, I., Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia
Non-alcoholic fatty liver disease (NAFLD) is still and will become a major problem worldwide as its prevalence is increasing. The new proposed term metabolic associated fatty liver disease (MAFLD) has opening the new horizon from the old dominant liver disease to metabolic associated liver disease. Gut microbiota dysbiosis is considered as “a man behind the gun”, not only causing a problem in the gut but also in other organs. Since gut microbiota also has a strong link to metabolic dysfunction, this chapter discusses gut microbiota dysbiosis in NAFLD, starting from the basic science until the most recent clinical evidence. © 2022 Elsevier Inc. All rights reserved.
Diabetes mellitus; Gut dysbiosis; Gut microbiota; Hypertension; Intestinal mucosal barrier; Intra-extra hepatic malignancy; Liver fibrosis; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity
Elsevier
9780128192658; 9780128220368
Book Chapter
#N/A
#N/A
#N/A